Trial Profile
Tumour biomarkers for sunitinib response in patients with advanced renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 17 Aug 2015 New trial record